Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

  • Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-021-00395-4, published online 30 May 2021

Download full text files

Export metadata

Metadaten
Author:Mike WenzelORCiDGND, Luigi NoceraORCiD, Claudia Collà RuvoloORCiD, Christoph WürnschimmelORCiDGND, Zhe Tian, Shahrokh F. ShariatORCiDGND, Fred SaadORCiDGND, Derya TilkiORCiDGND, Markus GraefenORCiDGND, Luis KluthORCiDGND, Alberto BrigantiORCiD, Philipp MandelORCiDGND, Francesco MontorsiGND, Felix ChunORCiDGND, Pierre I. KarakiewiczORCiD
URN:urn:nbn:de:hebis:30:3-752977
DOI:https://doi.org/10.1038/s41391-023-00656-4
ISSN:1476-5608
Publisher:Stockton Press
Place of publication:Basingstoke
Document Type:Article
Language:English
Date of Publication (online):2023/03/10
Date of first Publication:2023/03/10
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2024/07/18
Volume:26.2023
Page Number:2
First Page:1
Last Page:2
Note:
Korrektur zu: Wenzel, M., Nocera, L., Collà Ruvolo, C. et al. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00656-4
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International